Novavax Inc

$10.2
USD
Last updated on --.
24h volume3.08M
24h highest10.3150 USD
24h lowest9.9400 USD
24h Price movement-0.10%

NVAX recent prices

24 Hours
-0.10%-$0.01
30 days
+24.01%+$1.945
60 days
+26.04%+$2.075
90 days
+0.65%+$0.065

Key data

Previous close10.2100 USD
Market cap1.80B USD
Volume3.08M
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount0.10625 USD
Next ex-dividend dateDec 13, 2007
Next payment dateDec 31, 2007
EPS diluted (TTM)-0.53000 USD
Net income (FY)-87.84M USD
Revenue (FY)596.34M USD
Last report dateMay 6, 2026

About Novavax Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersGAITHERSBURG
Employees (FY)749.00
Revenue per employee (FY)796.18K USD
Net income per employee (FY)-117.27K USD
Listed onNasdaq
Official website

NVAX conversion tables

NVAXNVAX
USDUSD
0.5 NVAX5.100 USD
1 NVAX10.2 USD
5 NVAX51 USD
10 NVAX102 USD
USDUSD
NVAXNVAX
0.5 USD0.04902 NVAX
1 USD0.098039 NVAX
5 USD0.4902 NVAX
10 USD0.98039 NVAX

FAQ

NVAX is trading at $10.20, -0.10% over the last 24 hours. Track live moves on the price chart at the top of this page.
The NVAX stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. NVAX is currently trading at $10.20, -0.10% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on NVAX price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. NVAX's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from NVAX; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against NVAX's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Novavax Inc's market cap is currently 1.80B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume3.08M
24h highest10.3150 USD
24h lowest9.9400 USD
24h Price movement-0.10%
NVAXNVAX
USDUSD
Start trade with NVAX Perpetual